Key points are not available for this paper at this time.
Antithrombotic strategy in major ventricular dysfunction or HF remains unresolved; further RCTs needed before practice change.
The purpose of this review is to determine the risk of vascular occlusion due to either in situ thrombosis or thromboembolism in patients with major ventricular dysfunction with or without heart failure, and to determine whether such events can be reduced by ant it hrombotic therapy.
No takes yet. Share an insight, caveat, or question.
John G.F. Cleland (1997) studied this question.